That day, the Twitter account @EliLillyandCo posted ... Eli Lilly accounts had issued their fake insulin tweets, Eli Lilly’s stock share price tumbled by 4.37% or $16.08 down to $352.30 ...

I think the stock is a good pick to buy with the recent pullback. Forget last week's Twitter tumult. Lilly is a verified winner. 10 stocks we like better than Eli Lilly and Company When our award ...

Insulin producer Eli Lilly faces the economic ... producer saw a 4.5 percent drop in its stock and had to issue a clarification on its official Twitter account, @LillyPad. Mashable Trend Report ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald Trump would sign an order lowering drug prices.

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Wall Street Bulls Berenberg: Out of the gate, Berenberg analyst Kerry Holford lifted the firm’s price target on Eli Lilly stock by 17.6% to $1,000 from $850 and maintained a buy rating. The new ...

If you wait for a top growth stock to come down to a P/E of 20 or less, you may end up waiting forever and missing out on the opportunity completely. For years, Eli Lilly has been generating solid ...

But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk ...

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. REUTERS Lilly’s stock was recently up 14% at $838.80 in ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.